Nadim Srour1, Cecilia Chaparro2, Katherine Vandemheen3, Lianne G Singer4, Shaf Keshavjee4, Shawn D Aaron5. 1. Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Québec, Canada; Faculty of Medicine, McGill University, Montréal, Québec, Canada; Division of Pulmonology, Department of Medicine, Hôpital Charles-LeMoyne, Greenfield Park, Québec, Canada; Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Mount Sinai Hospital Centre, Montréal, Québec, Canada. Electronic address: nadim.srour@usherbrooke.ca. 2. Toronto Lung Transplant Program, University of Toronto, University Health Network, Toronto, Ontario, Canada; Adult Cystic Fibrosis Clinic St. Michael's Hospital, Toronto, Ontario, Canada. 3. Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. 4. Toronto Lung Transplant Program, University of Toronto, University Health Network, Toronto, Ontario, Canada. 5. Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Faculty of Medicine, The University of Ottawa, Ottawa, Ontario, Canada.
Abstract
BACKGROUND: Compared with patients infected with unique strains of Pseudomonas aeruginosa, patients with cystic fibrosis who are infected with transmissible strains of P aeruginosa, such as the Liverpool epidemic strain, have a 3-fold greater risk of death or lung transplant. We aimed to determine if pre-operative infection with transmissible strains of P aeruginosa was similarly associated with poor health outcomes after lung transplant. METHODS: We had prospectively identified and characterized endobronchial infections in 446 adult cystic fibrosis patients in Ontario, Canada, from September 2005 until December 2009. P aeruginosa isolated from sputum taken at 3-month intervals was genotyped, and patients were characterized as being infected with 1 of 2 transmissible strains or, alternatively, with unique strains of P aeruginosa. We monitored patients until 2013 and collected data on patients from the cohort who subsequently received a lung transplant. The primary outcome was survival after transplantation. RESULTS: We identified 56 lung transplant recipients from the cohort of 446 patients, including 18 infected with transmissible strains of P aeruginosa and 26 infected with unique P aeruginosa strains. Post-transplant survival at 3 years was 86% in the transmissible group and 84% in the unique group (p = 0.65). No significant differences between groups were found regarding bronchiolitis obliterans-free survival, the frequency of acute rejection episodes, the frequency of post-transplant respiratory tract infection, or the rate of change of post-transplant forced expiratory volume in 1 second. CONCLUSIONS: Pre-operative infection with transmissible strains of P aeruginosa is not associated with poorer post-transplant outcomes compared with patients infected with unique strains of P aeruginosa.
BACKGROUND: Compared with patients infected with unique strains of Pseudomonas aeruginosa, patients with cystic fibrosis who are infected with transmissible strains of P aeruginosa, such as the Liverpool epidemic strain, have a 3-fold greater risk of death or lung transplant. We aimed to determine if pre-operative infection with transmissible strains of P aeruginosa was similarly associated with poor health outcomes after lung transplant. METHODS: We had prospectively identified and characterized endobronchial infections in 446 adult cystic fibrosispatients in Ontario, Canada, from September 2005 until December 2009. P aeruginosa isolated from sputum taken at 3-month intervals was genotyped, and patients were characterized as being infected with 1 of 2 transmissible strains or, alternatively, with unique strains of P aeruginosa. We monitored patients until 2013 and collected data on patients from the cohort who subsequently received a lung transplant. The primary outcome was survival after transplantation. RESULTS: We identified 56 lung transplant recipients from the cohort of 446 patients, including 18 infected with transmissible strains of P aeruginosa and 26 infected with unique P aeruginosa strains. Post-transplant survival at 3 years was 86% in the transmissible group and 84% in the unique group (p = 0.65). No significant differences between groups were found regarding bronchiolitis obliterans-free survival, the frequency of acute rejection episodes, the frequency of post-transplant respiratory tract infection, or the rate of change of post-transplant forced expiratory volume in 1 second. CONCLUSIONS: Pre-operative infection with transmissible strains of P aeruginosa is not associated with poorer post-transplant outcomes compared with patients infected with unique strains of P aeruginosa.
Authors: Anna Engell Holm; Hans Henrik Lawaetz Schultz; Helle Krogh Johansen; Tania Pressler; Thomas Kromann Lund; Martin Iversen; Michael Perch Journal: J Clin Med Date: 2021-03-19 Impact factor: 4.241